Market Place
Sourcing Support
Optinose Announces Reporting Date for Q3 2024 Financial Results
05 Nov 2024 //
GLOBENEWSWIRE
Optinose Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
16 Oct 2024 //
GLOBENEWSWIRE
Optinose Appoints Terry Kohler as Chief Financial Officer
07 Oct 2024 //
GLOBENEWSWIRE
New Data Highlight Benefits Of XHANCE In Rhinosinusitis
05 Sep 2024 //
GLOBENEWSWIRE
Optinose to Present at H.C. Wainwright 26th Annual Global Investment Conference
26 Aug 2024 //
GLOBENEWSWIRE
Optinose To Present At H.C. Wainwright Global Investment Conference
26 Aug 2024 //
GLOBENEWSWIRE
Optinose Reports Q2 2024 Results And Operational Highlights
08 Aug 2024 //
GLOBENEWSWIRE
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
02 Aug 2024 //
GLOBENEWSWIRE
Expanded Access to XHANCE with Addition to National Commercial Formularies
27 Jun 2024 //
GLOBENEWSWIRE
Optinose To Present At Wainwright BioConnect Conference
17 May 2024 //
GLOBENEWSWIRE
Optinose Reports Q1 2024 Results, Operational Highlights
14 May 2024 //
GLOBENEWSWIRE
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
10 May 2024 //
GLOBENEWSWIRE
Optinose Announces $55 Million Registered Direct Offering
09 May 2024 //
GLOBENEWSWIRE
Optinose Q1 2024 XHANCE Net Revenue $14.9M, Provides Corporate Update
25 Apr 2024 //
GLOBENEWSWIRE
Optinose to Present at the Needham Virtual Healthcare Conference
04 Apr 2024 //
GLOBENEWSWIRE
Updated: FDA expands label for nasal spray to treat chronic sinus inflammation
18 Mar 2024 //
ENDPTS
XHANCE Approved by FDA as First and Only Medication for Chronic Rhinosinusitis
16 Mar 2024 //
GLOBENEWSWIRE
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Optinose Announces the Publication of ReOpen Phase 3 Program Evaluating XHANCE
18 Jan 2024 //
GLOBENEWSWIRE
FDA asks for more data from Optinose, extends review time for nasal spray
07 Dec 2023 //
BIOSPACE
Optinose Announces 3-Month Extension of FDA Review Period for XHANCE
06 Dec 2023 //
GLOBENEWSWIRE
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
22 Nov 2023 //
GLOBENEWSWIRE
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
09 Nov 2023 //
GLOBENEWSWIRE
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
27 Oct 2023 //
GLOBENEWSWIRE
Optinose to Present at the 2023 Cantor Global Healthcare Conference
22 Sep 2023 //
GLOBENEWSWIRE
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
10 Aug 2023 //
GLOBENEWSWIRE
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5M
27 Jul 2023 //
GLOBENEWSWIRE
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16 Jun 2023 //
GLOBENEWSWIRE
Optinose to Present at the Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
11 May 2023 //
GLOBENEWSWIRE
Optinose Announces FDA Acceptance of Supplemental NDAfor XHANCE
04 May 2023 //
GLOBENEWSWIRE
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
01 May 2023 //
GLOBENEWSWIRE
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Apr 2023 //
GLOBENEWSWIRE
Optinose to Present at the Needham Virtual Healthcare Conference
12 Apr 2023 //
GLOBENEWSWIRE
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results
07 Mar 2023 //
GLOBENEWSWIRE
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
21 Feb 2023 //
GLOBENEWSWIRE
Optinose Announces CEO Transition and Business Update
31 Jan 2023 //
GLOBENEWSWIRE
Optinose Appoints Paul Spence as Chief Commercial Officer
15 Dec 2022 //
GLOBENEWSWIRE
Optinose Announces Departure of Acting Chief Financial Officer
09 Dec 2022 //
GLOBENEWSWIRE
Optinose Announces Corporate Updates and Presentation at the 34th Annual PSHC
30 Nov 2022 //
GLOBENEWSWIRE
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
21 Nov 2022 //
GLOBENEWSWIRE
Optinose Announces Proposed Public Offering of Common Stock and Warrants
21 Nov 2022 //
GLOBENEWSWIRE
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
10 Nov 2022 //
GLOBENEWSWIRE
Optinose Announces ReOpen2 Presentation at the (ACAAI) 2022 Annual Meeting
09 Nov 2022 //
GLOBENEWSWIRE
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
07 Nov 2022 //
GLOBENEWSWIRE
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
21 Oct 2022 //
GLOBENEWSWIRE
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American
06 Sep 2022 //
GLOBENEWSWIRE
Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations
13 Jul 2022 //
GLOBENEWSWIRE
Optinose Announces Additional Positive Results from ReOpen2
08 Jul 2022 //
GLOBENEWSWIRE
Optinose Looking For A Partner To Optimize Big Opportunity In Chronic Sinusitis
14 Jun 2022 //
PHARMAINTELLIGENCE
Optinose Announces Positive Top-line Results of PIII Trial of XHANCE
13 Jun 2022 //
GLOBENEWSWIRE
Optinose Announces Departure of Chief Financial Officer
03 Jun 2022 //
GLOBENEWSWIRE
Optinose Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Optinose Announces Reporting Date for First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Optinose to Present at the Needham Virtual Healthcare Conference
08 Apr 2022 //
GLOBENEWSWIRE
Optinose Reports Q4 and FY 2021 Financial Results
08 Mar 2022 //
GLOBENEWSWIRE
Nasal spray maker clinches first PhIII win to reach bigger market
08 Mar 2022 //
ENDPTS
